Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway

Documenti analoghi

• ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
  di: Engelman, Jeffrey A., et al.
  Pubblicazione: (2005)
• Acquired Long QT Syndrome and Phosphoinositide 3-kinase
  di: Cohen, Ira S., et al.
  Pubblicazione: (2017)
• Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib‐resistant lung adenocarcinoma cells
  di: Ni, Jie, et al.
  Pubblicazione: (2018)
• Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
  di: SONG, ZHENGBO, et al.
  Pubblicazione: (2013)
• The phosphoinositide-3-kinase inhibitor PX-866 overcomes resistance to the EGFR inhibitor gefitinib in A-549 human non small cell lung cancer xenografts.
  di: Ihle, Nathan T., et al.
  Pubblicazione: (2005)